iSpecimen Unveils Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently Find Desired Biospecimens for Research

Enhanced iSpecimen Marketplace Search Interface

iSpecimen’s enhanced Marketplace now enables more precise specimen matching through an easy-to-use interface that allows researchers to search for desired samples via a Google-like search bar, as well as access new data fields and expanded searchable data, such as smoking and alcohol history.
iSpecimen’s enhanced Marketplace now enables more precise specimen matching through an easy-to-use interface that allows researchers to search for desired samples via a Google-like search bar, as well as access new data fields and expanded searchable data, such as smoking and alcohol history.

Updated Interface Provides Improved Search and Data Integration Capabilities

iSpecimen Marketplace Offers Millions of Biospecimens from Over 200 Providers in the Network

LEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a global, online marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare providers who have them, today unveiled its enhanced iSpecimen Marketplace® platform. The new software includes improved search and supplier data integration capabilities that have been designed to efficiently connect scientists with well-matched samples for their research, as well as help to increase supplier inventory utilization.

The platform’s redesigned, easy-to-use interface allows researchers to directly search for desired samples in iSpecimen’s provider network via a Google-like search bar. The technology utilizes researcher-specified broad or exact matching algorithms to find the precise human biospecimens that researchers need. Augmenting this updated search capability are facets that guide researchers to further refine their results. The search functionality now includes new data fields that can be accessed along with other features, such as multi-select and in-facet search, to enable a more powerful specimen matching capability.

A graphic accompanying this announcement is available at

The iSpecimen Marketplace also includes new features that enable specimen providers, including biobanks, to more effectively provide their specimens to researchers. Suppliers can now use the iSpecimen Marketplace technology to search their own inventory and easily find specimens that meet criteria for internal research requests. Additionally, new data integration capabilities, such as automated data harmonization and ingestion tools, allow healthcare providers’ inventories to be added quickly and maintained easily. Access to the iSpecimen Marketplace platform is free for participating suppliers and researchers alike upon signup.

Other new iSpecimen Marketplace features include expanded searchable data, such as smoking and alcohol history of the person from whom the sample was collected, and synonym support, which allows users to type common words into the search bar that will then automatically match to synonymous values stored in the iSpecimen Marketplace.

“For researchers around the world, obtaining quality specimens in a timely manner has never been an easy feat, and simplification starts with the search function,” said Dr. Christopher Ianelli, M.D., Ph.D., iSpecimen Founder and CEO. “Since the Company’s inception, demand for our iSpecimen Marketplace continues to grow. As such, we have worked vigorously to continue innovating our search function to streamline access to biospecimens, patients and data that are critical to advancing medical research and delivering results that align with precise banked specimen requirements. We look forward to continuing to make strategic, large-scale investments in the iSpecimen Marketplace that will optimize search results and assist researchers in need of specimens for critical research across the world. This is just the first in a series of developments that will help take biospecimen matchmaking and procurement to new heights.”

About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the Securities and Exchange Commission, which are available for review at Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Allison Soss

Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino

error: Content is protected !!